ArticleCureus2025
Association Between Transvaginal Ultrasound Measurement of Endometrial Thickness With Serum Estrogen Level in Post-menopausal Women in a Tertiary Care Centre.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Estrogen plays a vital role in endometrial physiology, and its deficiency in postmenopausal women leads to endometrial atrophy. However, residual or elevated estrogen levels - endogenous or exogenous - can stimulate endometrial thickening, which may signal an underlying pathology. Transvaginal ultrasound (TVUS) offers a non-invasive, practical method to measure endometrial thickness (ET), potentially serving as a surrogate marker for systemic estrogen exposure. This prospective observational study aims to correlate serum estradiol levels with endometrial thickness in postmenopausal women and to analyze the association between endometrial thickness and known estrogen-related risk factors. Methods A total of 100 postmenopausal women attending the gynaecology outpatient department at Sree Balaji Medical College and Hospital, Chennai, over a span of two years, from 2023 to 2025, were evaluated using TVUS for endometrial thickness and serum assay for estradiol levels. Baseline characteristics and comorbid conditions such as obesity, diabetes mellitus, hypertension, and parity status were recorded. Statistical analysis was used to assess correlations and significance. Results The mean endometrial thickness was 6.1±2.3 mm, and the mean serum estradiol level was 24.8±9.6 pg/mL. A moderate to strong positive correlation (r=0.78, p<0.001) was observed between serum estradiol levels and endometrial thickness. Endometrial thickness >4 mm was significantly associated with obesity (p=0.003), diabetes mellitus (p=0.005), and nulliparity (p = 0.008), but not with hypertension (p=0.082). Conclusion Serum estradiol levels may act as a surrogate biochemical marker for increased endometrial thickness in postmenopausal women. While elevated estrogenic activity can contribute to endometrial proliferation, increased endometrial thickness should not be interpreted in isolation as a direct indicator of high estrogen levels. Integrating serum hormone evaluation with TVUS findings and clinical risk profiling may enhance the early identification of women predisposed to estrogen-related endometrial pathology, particularly in postmenopausal care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.